Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients

Atsunori Kashiwagi1,*, Shinchi Araki2, Hiroshi Maegawa2

1Kusatsu General Hospital, Kusatsu, Japan, and 2Department of Medicine, Shiga University of Medical Science, Otsu, Japan

Keywords
Heart failure, Sodium–glucose cotransporter 2 inhibitor, Type 2 diabetes mellitus

*Correspondence
Atsunori Kashiwagi
Tel.: +81-77-563-8866
Fax: +81-77-565-9313
E-mail address: kashiwagi@kusatsu-gh.or.jp

J Diabetes Investig 2021; 12: 6–20
doi: 10.1111/jdi.13329

ABSTRACT
Recent major clinical trials of the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes have shown that they reduce three-point major adverse cardiovascular events, cardiovascular death, hospitalization for heart failure (HF) and a composite renal outcome. These beneficial effects of SGLT2 inhibitors are also evident in type 2 diabetes patients with a previous history of atherosclerotic cardiovascular disease or advanced renal disease. HF is a major determinant of the prognosis of diabetes patients. Although HF with low ejection fraction can be effectively treated with antihypertensive drugs, these treatments do not reduce mortality in HF patients with preserved ejection fraction (HFpEF). HFpEF is clinically characterized by left ventricular diastolic dysfunction, perivascular fibrosis and stiffness of cardiomyocytes, defined as “cardiomyopathy”. Therefore, HFpEF is considered to be an entirely separate entity to HF with low ejection fraction. Recent studies have suggested that HFpEF might be treatable using SGLT2 inhibitors, which ameliorate visceral adiposity, insulin resistance, hyperglycemia, hyperlipidemia, volume overload, hypertension and cardiac inflammation. In the final part of the present review, we discuss the biochemical and molecular mechanisms of the effects of SGLT2 inhibitors in type 2 diabetes patients with HFpEF. These involve amelioration of the low nitric oxide production and oxidative stress, a reduction in cardiac inflammatory cytokine signaling, inhibition of Ca2+ overload, and an improvement in cardiac energy metabolism as a result of ketone body production. Investigations of the beneficial effects of SGLT2 inhibitors on cardiorenal outcomes, including hospitalization for HF, are now being carried out in preclinical and clinical studies.

INTRODUCTION
Sodium–glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral glucose-lowering drug that inhibits renal glucose reabsorption, thereby increasing urinary glucose loss and causing osmotic diuresis in people with and without diabetes. SGLT2 inhibitor administration causes a urinary loss of 60–100 g glucose per day, which induces a negative energy balance, resulting in a significant change in whole-body energy metabolism1–7. Plasma glucose and insulin concentrations are significantly reduced in type 2 diabetes patients by treatment with SGLT2 inhibitors, and those are associated with significant improvements in both insulin resistance and insulin secretion8–11. In addition, SGLT2 inhibitors increase glucagon secretion through direct stimulation of pancreatic α-cells12. As a result, they reduce hepatic triglyceride synthesis, fat deposition in the liver and serum triglyceride concentration, and increase hepatic ketone body production5–7,11. Furthermore, the greater urinary glucose loss increases urinary uric acid excretion, resulting in a reduction in serum uric acid concentration13. Therefore, SGLT2 inhibitor treatment has beneficial effects on multiple atherogenic risk factors in patients with type 2 diabetes. SGLT2 inhibitors also have hemodynamic effects: they increase urinary water excretion and sodium loss, resulting in reductions in bodyweight, and both systolic and diastolic blood pressure14–19. These metabolic and hemodynamic effects of SGLT2 inhibitors have already been extensively reviewed19.

Almost all the cardiovascular risk factors commonly found in patients with metabolic syndrome are significantly
ameliorated by treatment with ipragliflozin, as shown in a pooled analysis of six Japanese phase II and III randomized controlled trials (RCTs)21. These beneficial effects on hemodynamic and metabolic parameters might also protect against the progression of atherogenic cardiovascular disease (CVD) in type 2 diabetes patients. Indeed, SGLT2 inhibitor treatment in type 2 diabetes patients with high cardiovascular risk consistently has reduced the incidence of hospitalization for heart failure (HHF), cardiovascular (CV) death and a renal composite outcome (RCO) in four multicenter RCTs22–27.

Interestingly, major multicenter clinical RCTs found that glucagon-like peptide-1 receptor agonists also effectively protect against not only cardiovascular events, but also progression of renal disease, which is consistent with the results found in the use of SGLT2 inhibitors. In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, liraglutide treatment for 3.8 years significantly reduced major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke with a hazard ratio (HR) of 0.87 (P < 0.01) compared with placebo28. In the Trial to Evaluate Cardiovascular and Other Long term Outcomes with semaglutide in patients with Type 2 Diabetes (SUSTAIN 6), semaglutide treatment for 2.1 years showed a HR of 0.74 for MACE (P < 0.02)29. However, the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) showed a HR for MACE that did not reach the threshold for demonstrated superiority versus placebo29. Taken together, it appears that among patients with established CVD, both liraglutide and semaglutide might provide cardiovascular benefits, but exenatide is less certain in regard to clinical benefits. Furthermore, protection against HHF has not been reported to be statistically significant with the use of any glucagon-like peptide-1 receptor agonists, which is entirely different from the results of treatment with SGLT2 inhibitors. The mechanisms to explain those differences between two types of drugs have not been extensively compared in the previous studies. Based on the evidence from recent major multicenter clinical RCTs, both SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists have been used as medicines to effectively protect not only cardiovascular events, but also progression of renal disease28–29, but also some evidence of type 2 diabetes patients to improve their life prognosis. We then summarize the subcellular biochemical and molecular mechanisms involved in the development of heart failure with preserved ejection fraction (HFpEF), and discuss the effectiveness of SGLT2 inhibitors for the treatment of HFpEF and HF with low ejection fraction (HFrEF) in diabetes patients.

**LARGE MULTICENTER PLACEBO-CONTROLLED RCTS OF THE USE OF SGLT2 INHIBITORS FOR THE PREVENTION OF CARDIORENAL DISEASES**

**Reduction of the incidence of MACE**

Four major multicenter RCTs of the use of SGLT2 inhibitors for the prevention of cardiorenal outcomes in diabetes patients were published between 2015 and 2019. Excellent reviews of the relationship between patient characteristics and cardiovascular outcomes in these four trials, and the mechanisms of these cardiovascular benefits have already been published33–35, and the characteristics of the participants in the four trials are shown in Table 1. These trials were the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial22–24, which involved the administration of 10 or 25 mg empagliflozin daily; the Canagliflozin Cardiovascular Assessment Study (CANVAS)25, which involved the administration of 100 mg or 300 mg canagliflozin daily; the Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial26, which involved the administration of 10 mg dapagliflozin daily; and the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial27, which involved the administration of 100 mg canagliflozin daily.

The primary end-points of each trial were evaluated after a mean follow-up period of 2.4–4.2 years. The baseline characteristics of the recruited patients are summarized in Table 1. They had a mean glycated hemoglobin of 8.1–8.3%, and renin–angiotensin–aldosterone system inhibitors and statins were used in >75% and 80% of patients, respectively. Reductions in glycated hemoglobin, bodyweight and systolic/diastolic blood pressure of 0.24–0.58%, 0.8–1.8 kg and 3–4 mmHg/0.36–1.39 mmHg were achieved, respectively. These drug effects were similar among the four trials of SGLT2 inhibitors, but there were clear differences in some of the baseline cardiorenal risk factors in the diabetes patients in these trials (Table 2). Almost all the participants (99%) in the EMPA-REG OUTCOME trial had a previous history of CVD, 40% had a mean urinary albumin-to-creatinine ratio (UACR) above the microalbuminuric threshold, and 26% had an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m². However, the participants in the CREDENCE trial had the most advanced renal disease of the four clinical trials, with 99.3% having an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m². In contrast, the participants in the Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial had the lowest cardiorenal risk, with just 41% having a previous history of CVD, 30% having a mean UACR above the microalbuminuric threshold and 7% having an eGFR <60 mL/min/1.73 m².
A total of 66% of the participants in CANVAS had a previous history of CVD (65.6%), 30.2% had a mean UACR above the microalbuminuric threshold and 20.1% had an eGFR < 60 mL/min/1.73 m², showing that they had a prevalence of cardiorenal comorbidities between the EMPA-REG OUTCOME and DECLARE-TIMI 58 trials.

The EMPA-REG OUTCOME trial of 7,020 type 2 diabetes patients showed that empagliflozin administration was associated with a 14% lower incidence ($P = 0.04$) of MACE after a mean of 3.1 years (Table 3). Similarly, in the CREDENCE trial, patients treated with 100 mg canagliflozin daily had a 20% lower incidence ($P = 0.01$) of MACE than those administering the placebo after a median of 2.62 years (Table 3). However, in the CANVAS study cohort, 10,142 type 2 diabetes patients were assigned to receive canagliflozin (100 mg, with the option to increase this to 300 mg, daily) or placebo for a median of 2.4 years (Table 3). The reduction in the incidence of MACE in the canagliflozin group versus the placebo group was not significant (HR 0.86, $P = 0.08$). Finally, the DECLARE-TIMI 58 trial included 17,160 type 2 diabetes patients who were followed for a median of 4.2 years. The patients in that trial had lower CVD risk and were at an earlier stage of CKD than those in the CREDENCE trial, the EMPA-REG OUTCOME trial and CANVAS, as shown in Table 2. Also in the DECLARE-TIMI 58 trial, the reduction in the incidence of MACE in the dapagliflozin group was not significantly different from that in the

### Table 1 | Baseline characteristics of the type 2 diabetes patients in the four clinical trials in which the preventive effects of sodium–glucose cotransporter 2 inhibitors against cardiorenal events were investigated

| Study           | EMPA-REG OUTCOME | CANVAS | DECLARE-TIMI 58 | CREDENCE |
|-----------------|------------------|--------|----------------|---------|
| Patients enrolled (n) | 7,020            | 10,142 | 17,160         | 4,401   |
| Drug            | Empagliflozin    | Canagliflozin | Dapagliflozin | Canagliflozin |
| Dose            | 10 or 25 mg      | 100 or 300 mg | 10 mg       | 100 mg   |
| Median duration of follow up | 3.1 years     | 2.4 years | 4.2 years     | 2.62 years |
| Mean baseline HbA1c | 8.1%            | 8.2%    | 8.3%           | 8.3%    |
| Mean duration of diabetes | NA             | 13.5 years | 11 years  | 15.8 years |
| Baseline RAASI use | 81%             | ≥80%    | 81%           | 100%    |
| Baseline statin use | 77%             | 75%    | 75%           | NA      |
| HbA1c reduction | 0.24%            | 0.58%   | 0.42%          | 0.25%   |
| BW reduction    | 1.79 kg          | 1.6 kg  | 1.8 kg         | 0.8 kg  |
| Blood pressure (mmHg) reduction (SBP/DBP) | 2.96/0.36       | 3.93/1.39 | 2.7/0.7       | 3.30/0.95 |

**BW**, bodyweight; CANVAS, Canagliflozin Cardiovascular Assessment Study; CREDENCE, Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; DBP, diastolic blood pressure; DECLARE-TIMI 58; Dapagliflozin Effect of Cardiovascular Events-Thrombolysis in Myocardial Infarction 58; EMPA-REG OUTCOME, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; HbA1c, glycated hemoglobin; NA, not available; RAASI, renin–angiotensin–aldosterone system inhibitor; SBP, systolic blood pressure.

### Table 2 | Previous history of cardiorenal risk factors and events in the type 2 diabetes patients enrolled in the four clinical trials of sodium–glucose cotransporter 2 inhibitors

| Study           | EMPA-REG OUTCOME | CANVAS | DECLARE-TIMI 58 | CREDENCE |
|-----------------|------------------|--------|----------------|---------|
| Mean eGFR (mL/min/1.73 m²) | 74              | 76.5   | 85.2           | 56.2    |
| eGFR (mL/min/1.73 m²) <60 | 25.9%          | 20.1%  | 7.4%            | 59.8%   |
| ≥60             | 74.1%            | 79.9%  | 92.6%           | 40.2%   |
| UACR (mg/gCr)   |                  |        |                 |         |
| <30             | 59.4%            | 69.8%  | 67.9%           | 0.7%    |
| 30–300          | 28.7%            | 22.6%  | 23.4%           | 11.3%   |
| >300            | 11.0%            | 7.6%   | 6.8%            | 88%     |
| Micro- and macroalbuminuria | 39.7%        | 30.2%  | 30.2%           | 99.3%   |
| Previous history of CVD | 99.2%        | 65.6%  | 41%             | 50%     |
| Previous history of HF | 10%            | 14.8%  | 10%             | 14.8%   |
| Existence of multiple CVD risks | NA            | Only two CVD risk factors (≥50 years) | 59%     | NA      |

CANVAS, Canagliflozin Cardiovascular Assessment Study; CREDENCE, Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; CVD, cardiovascular disease; DECLARE-TIMI 58; Dapagliflozin Effect of Cardiovascular Events-Thrombolysis in Myocardial Infarction 58; eGFR, estimated glomerular filtration rate; EMPA-REG OUTCOME, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; HF, heart failure; NA, not available; UACR, urinary albumin-to-creatinine ratio.
placebo group (HR 0.93, \( P = 0.17 \); Table 3). Therefore, the findings of the major RCTs suggest that SGLT2 inhibitor treatment is more likely to prevent MACE in patients with a higher CVD risk, a previous history of CV events and/or advanced renal disease.

**Reduction in the incidence of RCOs**

As shown in Table 4, the RCOs were defined as: (i) a sustained reduction of \( \geq 40\% \) in eGFR to \( < 60 \) mL/min/1.73 m\(^2\); (ii) a diagnosis of end-stage renal disease and dialysis for \( \geq 90 \) days; or (iii) kidney transplant or a sustained eGFR of \( < 15 \) mL/min/1.73 m\(^2\); with the addition of (iv) renal disease-related death in the DECLARE-TIMI 58 trial\(^{26,} \). There was a HR for this RCO of 0.53 (95% confidence interval [CI] 0.43–0.66) in the dapagliflozin group versus the placebo group. In CANVAS\(^{25} \), there was a HR of 0.60 (95% CI 0.47–0.77) for the RCO in the canagliflozin group versus the placebo group, in the EMPA-REG OUTCOME trial\(^{23,24} \), the equivalent HR was 0.54 (95% CI 0.47–0.75) for the empagliflozin group versus the placebo group, and in the CREDENCE trial, it was 0.66 (95% CI 0.53–0.81) for the canagliflozin group versus the placebo group.

These data showed that there were similar reductions in the risk of the RCO after treatment with various SGLT2 inhibitors, although there were some differences in the definitions of the RCO used among the four RCTs. However, we might add the following evidence that the absolute renal event rates were highest in the CREDENCE trial\(^{27} \), probably because the participants had the highest prevalence of comorbidities associated with advanced renal dysfunction and micro-/macroalbuminuria at baseline among the four trials.

**Reductions in the incidences of HHF and CV death**

The absolute incidences per 1,000 patient-years of HHF and CV death were significantly less after treatment with each of the SGLT2 inhibitors (HR 0.66–0.83) than in the control groups. The reductions in relative risk and the absolute event rate for HHF and CV death were greater in the EMPA-REG OUTCOME and CREDENCE trials than in the DECLARE-TIMI 58 trial and CANVAS (Table 5). However, the reduction in the relative risk of HHF alone was similar among the four trials (HR 0.61–0.73). Surprisingly, the reduction in HHF was evident after approximately 6 months of treatment with empagliflozin, suggesting that this effect might be independent of long-term improvements in cardiovascular risk factors.

**Comparison of the cardiorenal protection provided by SGLT2 inhibitors and other glucose-lowering drugs**

The cardiorenal protective effects of SGLT2 inhibitor treatment have been studied in real-world clinical practice. In the large Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT2 inhibitors observational study (CVD-REAL)\(^{36} \), the addition of an SGLT2 inhibitor was associated with reductions in the risks of all-cause death and HHF, regardless of the presence or absence of pre-existing CVD, compared with the use of other glucose-lowering drugs. Similarly, in the CVD-REAL2 study\(^{37} \), which was carried out with a variety of patients across a number of countries, the initiation of a different SGLT2 inhibitor was associated with reductions in the risks of CV events, including CV death (HR 0.52), HHF (HR 0.60), myocardial infarction (HR 0.81) and stroke (HR 0.68). Finally, CVD-REAL3 study\(^{38} \) aimed to determine the effects of SGLT2 inhibitors on the progression of renal dysfunction in type 2 diabetes patients with or without CKD, in routine clinical practice. The results showed that the initiation of SGLT2 inhibitor therapy in type 2 diabetes patients is associated with a smaller decline in kidney function and a lower incidence of a composite of renal events than the initiation of other glucose-lowering drugs.

**PREVENTION OF HEART FAILURE IN DIABETES PATIENTS IN THE TREATMENT WITH SGLT2 INHIBITORS**

**Heart failure in diabetes**

The current American College of Cardiology/American Heart Association guidelines define heart failure (HF) as a complex clinical syndrome\(^{39} \). HF is a major determinant of the prognosis of patients with diabetes mellitus. It is generally accepted that the prevalence of HF in diabetes is twice as high in men and fivefold as high in women with diabetes compared with

---

**Table 3 | Reductions in the incidence of major adverse cardiovascular events in type 2 diabetic patients induced by sodium–glucose cotransporter 2 inhibitors**

| Study               | MACES (per 1,000 patient-years) | Hazard ratio (95% CI) | P-value |
|---------------------|---------------------------------|-----------------------|---------|
|                     | SGLT2 inhibitor | Placebo  |                          |         |
| DECLARE-TIMI 58     | 22.6             | 24.2     | 0.93 (0.84–1.03)          | 0.17    |
| CANVAS             | 26.9             | 31.5     | 0.86 (0.75–0.97)          | 0.08    |
| EMPA-REG OUTCOME   | 37.4             | 43.9     | 0.86 (0.74–0.99)          | 0.04    |
| CREDENCE           | 38.7             | 48.7     | 0.80 (0.67–0.95)          | 0.01    |

CANVAS, Canagliflozin Cardiovascular Assessment Study; CI, confidence interval; CREDENCE, Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation; DECLARE-TIMI 58, Dapagliflozin Effect of Cardiovascular Events-Thrombolysis in Myocardial Infarction 58; EMPA-REG OUTCOME, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; MACES, major adverse cardiovascular events; SGLT2, sodium–glucose cotransporter 2.
Table 4 | Reductions in the incidences of composite renal-specific outcomes in type 2 diabetic patients induced by sodium–glucose cotransporter 2 inhibitors

| Study             | Event rates of a composite renal outcome (per 1,000 person-years) | Hazard ratio (95% CI) | P-value |
|-------------------|---------------------------------------------------------------|---------------------|---------|
| DECLARE-TIMI 58   | SGLT2 inhibitor 3.7, Placebo 7                                | 0.53 (0.43–0.66)    | <0.001  |
|                  |                                                              |                     |         |
| CANVAS           | SGLT2 inhibitor 5.5, Placebo 9                               | 0.60 (0.47–0.77)    | <0.001  |
|                  |                                                              |                     |         |
| EMPA-REG OUTCOME | SGLT2 inhibitor 6.3, Placebo 11.5                           | 0.54 (0.40–0.75)    | <0.001  |
|                  |                                                              |                     |         |
| CREDENCE         | SGLT2 inhibitor 28.7, Placebo 43.7                          | 0.66 (0.53–0.81)    | P < 0.001|

Table 5 | Reductions in the incidences of hospitalization for heart failure and cardiovascular death or hospitalization for heart failure in type 2 diabetes patients induced by sodium–glucose cotransporter 2 inhibitors

| Study             | Event rates for HHF and CV death (per 1,000 person-years) | Hazard ratio (95% CI) | P-value |
|-------------------|-----------------------------------------------------------|---------------------|---------|
| DECLARE-TIMI 58   | SGLT2 inhibitor 12.2, Placebo 14.7                       | 0.83 (0.73–0.95)    | 0.005   |
|                  |                                                             |                     |         |
| CANVAS           | SGLT2 inhibitor 16.3, Placebo 20.8                       | 0.78 (0.67–0.91)    | 0.0015  |
|                  |                                                             |                     |         |
| EMPA-REG OUTCOME | SGLT2 inhibitor 19.7, Placebo 30.1                       | 0.66 (0.55–0.79)    | <0.001  |
|                  |                                                             |                     |         |
| CREDENCE         | SGLT2 inhibitor 31.5, Placebo 45.4                       | 0.69 (0.57–0.83)    | <0.001  |

Age-matched non-diabetic individuals. In addition, older adult type 2 diabetes patients have a 1.3-fold greater risk of developing HF than age-matched non-diabetic individuals. Furthermore, it has been reported that patients with diabetic glomerulosclerosis, but without major coronary artery disease, cardiac hypertrophy or valvular heart disease develop HF, which has been defined as a novel type of cardiomyopathy. Therefore, it is possible that poor long-term glycemic control puts patients at a higher risk of developing not only diabetic retinopathy and nephropathy, but also cardiac microvascular complications with interstitial and perivascular fibrosis, and myocardial cell death, which are significant risk factors for the development of HF in diabetes.

HF with preserved ejection fraction in diabetes

HF can be classified into three types, the first two of which are HFrEF (ejection fraction [EF] <40%) and HfPEF (EF ≥50%). Values of EF of 40–49% are defined as midrange. HfPEF is clinically characterized by poor diastolic function, and the wider clinical characteristics of patients with HfPEF are listed in Figure 1. This type of HF is reported to be highly prevalent in patients with hypertension, diabetes, obesity, metabolic syndrome or chronic kidney disease. It has also been shown that multiple parameters associated with high diastolic left ventricular stiffness negatively correlate with glycated hemoglobin in type 2 diabetes patients, without evidence of abnormal wall movement or systolic ejection fraction.

The significance of diabetic microvascular complications for the risk of HF in diabetes has also been studied. In the Can-desartan in Heart Failure: Assessment of Resolution in Mortality and Morbidity (CHARM) trial, the risks of CV death and HF were studied in a population containing patients with HFrEF or HfPEF and with or without diabetes. The results showed that diabetes patients had higher risks of CV death and HF than patients without diabetes. Furthermore, the incidence of HF in diabetes patients was reported to be almost twice that of non-diabetic patients, irrespective of the presence of either HfPEF or HFrEF. In addition, the prognosis of diabetes with or without microangiopathy was compared with that of non-diabetic patients, all of whom had HfPEF, in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial (TOPCAT). The cumulative incidences of HFH and CV death were significantly higher in diabetes patients with any type of microvascular complication than in non-diabetic or diabetes patients without microangiopathy. These results suggest that the existence of microvascular complications in diabetes patients with HfPEF might increase the risks of both CV death and HF.
Mechanisms of progression of HFpEF in diabetes
As shown in Figure 2, type 2 diabetes patients mostly fit into two categories with regard to their progression to HF. One category comprises type 2 diabetes patients with visceral obesity, and insulin resistance, hyperinsulinemia, lipid abnormalities and/or hypertension, who are at higher risk of developing acute coronary syndrome. Once these patients develop acute coronary syndrome, they might also develop acute or chronic left ventricular systolic dysfunction, which is classified as HFrEF45. However, obesity and type 2 diabetes might also lead to HFpEF, which is induced by an increase in cardiac pre-load, developing because of volume overload due to plasma volume expansion. Furthermore, in such patients, insulin resistance and pro-inflammatory cytokines released from hypertrophied visceral adipocytes cause arterial stiffness, endothelial dysfunction in arterioles, and a reduction in capillary density systemically and in the heart, which results in an increase in cardiac afterload50–52. These pathophysiological states are highly prevalent in obese type 2 diabetes patients. The obesity-induced accumulation of cardiovascular risk factors has been studied in pigs fed a high-fat diet and in which hypertension was induced by renal artery embolization, over a 6-month period. These animals showed systemic inflammation, greater myocardial superoxide production, greater endothelial nitric oxide synthase (eNOS) uncoupling and lower nitric oxide production, and an impairment in endothelial-dependent vasodilatation in small coronary arteries53,54.

The second category includes patients with long-standing type 2 diabetes complicated by the presence of severe diabetic nephropathy and/or retinopathy, and type 1 diabetes patients with poor long-term glycemic control. This second group of patients are characterized by diffuse narrowing and heavy sclerosis of distal coronary arteries, perivascular fibrosis, the deposition of a large amount of extracellular matrix, and the formation of advanced glycation end-products in cardiac muscle and intracardiac vascular walls, without major coronary artery stenosis. These changes are characteristic of “diabetic cardiomyopathy”42–44.

A new strategy for the treatment of HFrEF using SGLT2 inhibitors
Studies of a number of drugs, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, mineralocorticoid receptor antagonists, diuretics and sacubitril/valsartan (a combination of a neprilysin inhibitor and an angiotensin receptor blocker) have shown that they reduce the risk of mortality in patients with HFrEF32,55,56. Neprilysin is a zinc-dependent metalloprotease that cleaves peptides at the amino side of hydrophobic residues, thereby inactivating several peptide hormones, including glucagon, brain natriuretic peptide and bradykinin. Therefore, the beneficial clinical effects of the neprilysin inhibitor, sacubitril, might relate to its inhibition of vasoactive peptide degradation. In addition, the efficacy of SGLT2 inhibitors for the prevention of HHF has been studied in 4,744 patients with symptoms of HF, New York Heart Association (NYHA) stage II–IV and EF ≤40%. The participants were treated with 10 mg dapagliflozin or placebo once daily for a median of 18.2 months57, and deterioration in HF occurred in 16.3% of those in the dapagliflozin group, but 21.2% of those in the placebo group (HR 0.74, 95% CI 0.65–0.85; P < 0.001). This protective effect of dapagliflozin was similar in patients with or without diabetes.

The use of SGLT2 inhibitors for the treatment of patients with type 2 diabetes and HFpEF
HFpEF is considered to be an entirely separate entity to HFrEF and is present in nearly 50% of patients with HHF. Multicenter RCTs have not shown a reduction in the incidence of mortality
in patients with HFpEF that were treated with RASs, angiotensin-converting enzyme inhibitors, β-blockers, or sacubitril/valsartan. Although TOPCAT showed that spironolactone treatment reduced the incidence of HHF (HR 0.83, 95% CI 0.69–0.99, P = 0.04) in patients with HFpEF, it did not reduce the incidences of total death or hospitalization for any reason. Furthermore, this treatment was associated with an increase in serum creatinine concentration and hyperkalemia. Therefore, the use of mineralocorticoid receptor antagonists has not been recommended for the treatment of patients with HFpEF. As a result, a new approach to the diagnosis and treatment of HFpEF in diabetes has been sought.

Recently, there have been many studies that show that SGLT2 inhibitors improve ventricular diastolic function and the micro- and macrovascular circulation in diabetes patients with HF. A prospective multicenter study of type 2 diabetes patients with stable HF was carried out, in which patients with HFpEF and HFrEF + HF with midrange EF (31%) were administered with 5 mg/day dapagliflozin for 6 months. This showed a significant reduction in the ratio of mitral inflow E to mitral
e’ annular velocity (E/e’) from 9.3 to 8.5 cm/s (P < 0.02) in response to dapagliflozin treatment. Although this was an observational, follow-up study without a control group, the findings suggested that SGLT2 inhibitors might be beneficial for treatment of left ventricular diastolic dysfunction in diabetes. In another study, empagliflozin was shown to significantly reduce diastolic tension, without affecting systolic function, which was assessed in vitro using ventricular trabeculae isolated from patients with end-stage systolic HF. In addition, empagliflozin had a beneficial effect to reduce passive myofilament stiffness by increasing the phosphorylation of myofilament regulatory proteins.

In CANVAS, EF was measured by echocardiography as part of the routine clinical care of the participants, and the incidence of HF was compared between participants with HFpEF (EF ≥50%) and HFrEF (EF <50%). This analysis showed that the protective effects of canagliflozin against HF did not significantly differ between patients in these two categories and, thus, provided some hope that HFpEF might be ameliorated by SGLT2 inhibitor treatment in diabetes patients. Furthermore, in a subanalysis of the DECLARE-TIMI 58 data, the ability of dapagliflozin to prevent CV death and HHF was compared in participants with low ventricular EF (EF <45%) and those without HFrEF. Of the 17,160 participants, 671 (3.9%) had HFrEF, 1,316 (7.7%) had HF without a known reduction in EF and 15,173 (88.4%) had no history of HF at baseline. The results showed that dapagliflozin reduced the incidences of CV death more significantly in patients with HFrEF (HR 0.62, 95% CI 0.45–0.86) than in those without HFrEF (HR 0.88, 95% CI 0.76–1.02). However, it significantly reduced HHF to a similar extent in patients with (HR 0.64) and without (HR 0.76) HFrEF. Further clinical trials of the efficacy of SGLT2 inhibitors for the prevention of cardiovascular events in patients with HFpEF and HFrEF are now ongoing.

**SUBCELLULAR, BIOCHEMICAL AND MOLECULAR MECHANISMS OF THE BENEFICIAL EFFECTS OF SGLT2 INHIBITORS ON HFpEF IN DIABETES PATIENTS**

The molecular mechanisms of the development of HFpEF in diabetes have been analyzed in a number of studies. The delineation of some of these mechanisms has suggested promising targets for the amelioration of HFpEF in patients with type 2 diabetes, and below we discuss the subcellular biochemical and molecular mechanisms whereby SGLT2 inhibitors might prevent HFpEF in diabetes (Figures 3,4).

**Effects of SGLT2 inhibitors on nitric oxide production and oxidative stress**

We have reported that insulin resistance is associated with poor endothelium-dependent vascular relaxation because of impairment in eNOS activity and greater production of the superoxide anion. In insulin resistance, eNOS uncoupling is principally induced by a deficiency of tetrahydrobiopterin (BH4; an active cofactor of eNOS) in vascular endothelial cells, which develops because of a reduction in BH4 biosynthesis secondary to lower activity of guanosine-triphosphate cyclohydrolase I. Furthermore, 7,8-dihydropteridine (BH2; the inactive form) concentration markedly increases because of a reduction in the activity of dihydropteridine reductase, the enzyme that catalyzes the conversion of BH3 to BH4. The resulting reduction in the BH4/BH2 ratio significantly reduces eNOS activity and increases peroxynitrite production in endothelial cells of insulin-resistant rats (Figure 3). The resulting increase in oxidative stress might cause higher expression of pro-inflammatory cytokines in cardiomyocytes. This exposure to pro-inflammatory cytokines and oxidative stress activates the Janus kinase-signal transduction and activator of transcription, nuclear factor-kappa B and Smad signaling pathways in cardiomyocytes. Interestingly, ipragliflozin administration significantly improves acetylcholine-dependent vasodilation in mice with streptozotocin-induced diabetes, potentially by ameliorating the impairment of eNOS, and reducing both reactive oxygen species generation in the endothelial cells of the abdominal aorta and inflammatory cytokine expression.

**SGLT2 inhibitors reduce pro-inflammatory cytokine secretion and the activation of downstream signaling pathways**

Inflammatory cytokines that are released from hypertrophic adipocytes activate cytokine signaling in cardiac tissue (the Janus kinase-signal transduction and activator of transcription, nuclear factor-kappa B, and Smad signaling pathways; Figure 3). Furthermore, transforming growth factor-β is released by activated macrophages and binds to its receptor on fibroblasts in cardiac tissue, which activates Smad signaling, resulting in greater synthesis of extracellular matrix proteins. Hyperglycemia-induced cardiac damage is also caused by an increase in reactive oxygen species, inflammation and apoptosis. Furthermore, it has been shown that greater release of pro-inflammatory cytokines by hypertrophic adipocytes stimulates the expression of inducible NOS in cardiomyocytes secondary to the activation of nuclear factor-kappa B. Thus, the oxidative stress that is induced by insulin resistance and hyperglycemia activates inflammatory cytokine signaling in cardiomyocytes.

Interestingly, the SGLT2 inhibitor ipragliflozin ameliorates diabetes and obesity-associated metabolic abnormalities in type 2 diabetes mice. In addition, 8 weeks of empagliflozin treatment significantly improves diabetic myocardial structure and function, and ameliorates fibrosis through inhibition of the transforming growth factor-β/Smad signaling pathway in diabetic KK-Ay mice. Furthermore, canagliflozin is superior to glimepiride with respect to its beneficial effects on adipose tissue function and serum leptin, adiponectin, and interleukin-6 concentrations, which are related to the reduction in CV risk.

Recently, further interesting work regarding the molecular mechanisms of the progression of HFpEF has been published. Overexpression of nitric oxide synthase (iNOS) induces reductions in the activities of two proteins: an isoform of X-box...
binding protein 1 (XBP1) and inositol-requiring enzyme 1α. Inositol-requiring enzyme 1α is responsible for the splicing of XBP1 messenger ribonucleic acid to yield XBP1s, and only this spliced form of XBP1 can efficiently activate the unfolded protein response. Thus, a reduction in XBP1s expression inhibits the unfolded protein response, which causes the myocardial accumulation of destabilized proteins and greater apoptosis of cardiomyocytes. In fact, Schiattarella et al. induced HFpEF in mice by feeding a high-fat diet, which involved the cardiac activation of iNOS, causing inflammation, and successfully induced hypertension with the use of Nω-nitro-1-arginine methyl ester, an inhibitor of eNOS. In addition, they also showed that a deficiency in iNOS expression or overexpression of XBP1s ameliorated the HFpEF phenotype in those mice, which was
associated with lower left ventricular filling pressure and less pulmonary congestion\textsuperscript{83}. Furthermore, inflammatory cytokines inhibit eNOS production, and reduce the activities of both soluble guanylate cyclase and protein kinase G in endothelial cells, which reduces the phosphorylation of titin\textsuperscript{84}, and overproduction of reactive oxygen might cause disulfide bonds to be established in titin molecules. Both of these changes alter the rigidity of titin, and lead to cardiac muscle stiffening. Therefore, SGLT2 inhibitors might be able to inhibit iNOS expression and activate eNOS, causing an increase in XBP1s expression and greater titin phosphorylation in cardiac muscle\textsuperscript{63}. This possibility is further tested in animal models of diabetes in future studies.

**Clinical significance of the inhibition of Na\textsuperscript{+}-H\textsuperscript{+} exchanger 1 in the diabetic myocardium by SGLT2 inhibitor treatment**

The Na\textsuperscript{+}-H\textsuperscript{+} exchanger (NHE1; the predominant isoform of NHE in cardiomyocytes) plays an important role in maintaining intracellular pH during myocardial ischemia, when the high intracellular H\textsuperscript{+} concentration activates NHE1, which reduces the cytosolic [H\textsuperscript{+}] by increasing cytosolic [Na\textsuperscript{+}], which activates...
the Na⁺-Ca²⁺ exchanger, leading to an increase in cytosolic [Ca²⁺]85. Interestingly, it has been reported that SGLT2 inhibitors might directly inhibit NHE1 in the myocardium (Figure 4)86. Dapagliflozin reduces the amplitude of cell shortening and the L-type Ca²⁺ current in ventricular cardiomyocytes from streptozotocin-treated rats, which implies that SGLT2 inhibitors have an acute negative inotropic effect in diabetic cardiomyocytes87. Consistent with this, empagliflozin reduces both cytosolic [Na⁺] and [Ca²⁺] during both systole and diastole, and increases mitochondrial [Ca²⁺] in rat cardiomyocytes88. These findings might reflect a greater mitochondrial capacity to synthesize adenosine triphosphate (ATP), restoring the energetic state of cardiomyocytes (Figure 4). Both dapagliflozin and canagliflozin also inhibit NHE1, and reduce cytosolic [Na⁺] in mouse cardiomyocytes and hearts89. Interestingly, SGLT2 inhibitors have high binding affinities for the extracellular Na⁺-binding site of NHE90. These data show that SGLT2 inhibitors might have an off-target effect on NHE1. In addition, it has been suggested that SGLT2 inhibitors promote natriuresis by inhibiting NHE3 activity in the proximal tubule90, which might represent an additional mechanism by which they reduce the incidence of HHF in diabetes patients.

Role of ketone bodies in amelioration of the cardiac energy crisis in diabetes patients with a failing heart by SGLT2 inhibitor treatment

Diabetes patients with cardiomyopathy and a failing heart often develop a cardiac energy crisis. Therefore, interventions that improve cardiac energy metabolism might be effective treatments for cardiac dysfunction in patients with diabetes. It is generally accepted that glucose utilization is significantly impaired in the diabetic heart, and ATP generation in cardiomyocytes is highly dependent on free fatty acid metabolism, which can adversely affect cardiomyocytes91. Furthermore, it has been reported that the myocardial uptake of glucose, lactate and pyruvate are lower, whereas that of ketone bodies is higher in individuals with diabetes than non-diabetic individuals92. The use of ketone bodies is more energetically efficient than fatty acid oxidation, because it yields more energy for ATP synthesis per molecule of oxygen93. Furthermore, the use of ketone bodies is associated with less mitochondrial uncoupling and oxidative stress94–96. During the development of cardiac hypertrophy and HF in mouse models, ketone oxidation increases in the heart, and ketone bodies become a key fuel source in the context of a lower capacity to oxidize fatty acids97. A vast quantity of evidence shows that the hepatic rate of ketogenesis is finely regulated by an orchestrated series of metabolic interactions between adipose tissue and the liver (Figure 4). Plasma ketone body concentrations increase in patients with diabetes treated with SGLT2 inhibitors because of greater ketogenesis in the liver and an increase in renal tubular reabsorption of ketone bodies98,99. In this way, SGLT2 inhibitors increase circulating ketone body concentrations100–102. Therefore, the effect of SGLT2 inhibitors to prevent HHF might be partly attributable to increases in plasma ketone body concentrations. Interestingly, a 3-h infusion of 3-hydroxybutyrate increased the plasma concentration of this ketone from 0.4 to 3.3 mmol/L (P < 0.001), which was accompanied by an 8% increase in cardiac output (P < 0.001). Furthermore, there was a dose-dependent relationship between the increase in plasma 3-hydroxybutyrate and cardiac output103. Therefore, therapeutic approaches aimed at increasing circulating ketone body concentrations in HF patients are currently under investigation in preclinical and clinical studies.

CONCLUSION

SGLT2 inhibitors effectively protect against major adverse cardiovascular events, especially in type 2 diabetes patients with a previous history of atherosclerotic cardiovascular disease and advanced renal disease. Furthermore, similar reductions in both HHP and RCOs occur in type 2 diabetes patients, regardless of the level of cardioenal risks. HF is a major clinical problem that determines the life expectancy of diabetes patients. One particular challenge is to protect diabetes patients against the development of HFpEF and HHeF. HFpEF is clinically characterized by diastolic dysfunction, which is highly prevalent in diabetes patients with multiple CV risks. It is generally accepted that SGLT2 inhibitors ameliorate visceral adiposity, insulin resistance, hyperglycemia, hyperlipidemia, volume overload and hypertension. Furthermore, it has also been suggested that SGLT2 inhibitor treatment ameliorates endothelial dysfunction, inflammatory cytokine signaling, the inhibition of Ca²⁺ overload as a result of the inhibition of NHE1 activity and mitochondrial dysfunction; and increases serum ketone body concentrations, which have been shown to ameliorate HFpEF in preclinical and clinical studies. In summary, we suggest that the use of SGLT2 inhibitors represents an effective new approach for the prevention of HFpEF in patients with diabetes.

ACKNOWLEDGMENTS

We thank Mark Cleasby, PhD, from Edanz Group (www.edanzediting.com/ac) for editing drafts of this manuscript.

DISCLOSURE

AK is a consultant for and has received consulting fees from the Sunstar group. HM has received lecture fees from MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Astellas Pharma Inc., Mitsubishi-Tanabe Pharma Corporation, Sanofi K.K., Takeda Pharmaceutical Co. Ltd., Daiichi SANKYO Co. Ltd., AstraZeneca K.K., Novo Nordisk Pharma Ltd., Sumitomo Dainippon Janssen Pharma Co. Ltd. and Eli Lilly; research support from Astellas Pharma Inc., AstraZeneca K.K., Nippon Boehringer Ingelheim Co. Ltd., Sunstar Inc., Mitsubishi Tanabe Pharma Corporation, Kyowa Kirin Co. Ltd., Nissan Chemical Corporation and MIKI Corporation; and research grants from Takeda Pharmaceutical Co. Ltd., Astellas Pharma Inc., MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Kyowa Kirin Co. Ltd.,
REFERENCES

1. Lee WS, Kanai Y, Wells RG, et al. The high affinity Na+/glucose cotransporter. J Biol Chem 1994; 269: 12032–12039.
2. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733–794.
3. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci 2011; 32: 63–71.
4. Abdul-Ghani M, DeFronzo RA, Norton L. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans. Diabetes 2013; 62: 3324–3328.
5. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2013; 124: 499–508.
6. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124: 509–514.
7. Cefalu WT. Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition. J Clin Invest 2015; 124: 485–487.
8. Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia 2014; 57: 891–901.
9. Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin. J Clin Invest 1987; 79: 1510–1515.
10. Takahara M, Shiraiwa T, Matsuoka T, et al. Ameliorated pancreatic B cell dysfunction in type 2 diabetic patients treated with a sodium-glucose co-transporter 2 inhibitor iragliflozin. Endocrine J 2015; 62: 77–86.
11. Leiter LA, Forst T, Polidori D, et al. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab 2016; 42: 25–32.
12. Bonner C, Kerr-Conte J, Grym V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015; 21: 512–517.
13. Chino Y, Sakukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 2014; 35: 391–404.
14. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose-cotransport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014; 8: 330–339.
15. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 2015; 38: 420–428.
16. Kashiwagi A, Yoshida S, Kawamura K, et al. Effects of ipragliflozin, a selective sodium–glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials. Diabetol Int 2017; 8: 76–86.
17. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262–275.
18. Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2014; 16: 1087–1095.
19. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020–1031.
20. Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium independent glucose co-transporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J Diabetes Investig 2017; 8: 416–427.
21. Kashiwagi A, Sakatani T, Nakamura I, et al. Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials. Endocrine J 2018; 65: 691–705.
22. Zimman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
23. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323–334.
24. Cherney DZ, Zinman B, Inzucchi SE, et al. OUTCOME Investigators. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: exploratory analysis from the EMPA-REG OUTCOME randomized, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5: 610–621.
25. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.
26. Vivlioti SD, Bonaca MP, Mosenzon O, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347–357.
27. Perkovic V, Jardine MJ, Neal S, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295–2306.
28. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–322.
29. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New Engl J Med 2016; 375: 1834–1844.
30. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. New Engl J Med 2017; 377: 1228–1239.
31. Mann JFE, Orsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377: 839–848.
32. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with EASD. Eur Heart J 2018; 39: 27–63.
33. Kluger AY, Tecson KM, Lee AY, et al. Class effects of SGLT2 inhibitors on cardiorenal outcomes. Cardiovasc Diabetol 2019; 18: 99.
34. Rabizadeh S, Nakhjavani M, Esteghamati A. Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review. Int J Endocrinol Metab 2019; 17: e84353.
35. Verma S, McMurray JJV. SGLT2 inhibitor and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologica 2018; 61: 2108–2117.
36. Cavender MA, Norhammar A, Birkeland KL, et al. SGLT2 inhibitors and cardiovascular risk: an analysis of CVD-REAL. J Am Coll Cardiol 2018; 71: 2497–2506.
37. Kosiborod M, Lam CSP, Kohsaka S, et al. Cardiovascular events associated with SGLT2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol 2018; 71: 2628–2639.
38. Heerspink HL, Karakol A, Thureron M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol 2020; 8: 27–35.
39. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guideline for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of cardiology (ESC). Eur Heart J 2016; 37: 2129–2200.
40. Bell DSH. Heart failure: the frequent, forgotten, and often lethal complication of diabetes. Diabetes Care 2003; 26: 2433–2441.
41. Nichols GA, Ephross SA, Gullion CM, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27: 1879–1884.
42. Rubler S, Drugul J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595–602.
43. Bell DSH. Diabetic cardiomyopathy. Diabetes Care 2003; 26: 2949–2951.
44. Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J 2015; 36: 1718–1727.
45. Shah S, Katz DH, Deo RC. Phenotypic spectrum of heart failure with preserved ejection fraction. Heart Fail Clin 2014; 10: 407–418.
46. Clarke GD, Molina-Wilkins M, Solis-Herrera C, et al. Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control. Endocrine Metab 2018; 1: e00014.
47. Tripiskias F, Giamouzis G, Parrissis J, et al. Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail 2016; 18: 744–58.
48. McMurray JJV, O’Stergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added Trial. Lancet 2003; 362: 767–771.
49. Sandesara PB, O’Neal WT, Kelli HM, et al. The prognostic significance of diabetes and microvascular complications in patients with heart failure with preserved ejection fraction. Diabetes Care 2018; 41: 150–155.
50. Tromp J, Lim SL, Toy WT, et al. Microvascular disease in patients with diabetes with reduced ejection fraction versus preserved ejection fraction. Diabetes Care 2019; 42: 1792–1799.
51. Packer M, Kitzman DW. Obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of aldosterone, norepinephrine, and sodium-glucose cotransporter-2. J Am Coll Cardiol 2018; 6: 633–639.
52. Bakker W, Eringa EC, Sipkema P, et al. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res 2009; 335: 165–189.
53. Sorop O, Heinonen I, van Kranenburg M, et al. Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening. Cardiovasc Res 2018; 114: 954–964.
54. Patel VB, Shah S, Verma S, et al. Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. Heart Fail Rev 2007; 12: 889–902.
55. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717.
66. Pabel S, Wagner S, Bollenberg H, et al. Empagliflozin directly improves diastolic function in human heart failure. *Eur J Heart Fail* 2018; 20: 1690–1700.

67. Figtree GA, Radholm K, Barrett TD, et al. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus: results from the CAVAS program. *Circulation* 2019; 139: 2591–2593.

68. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. *Circulation* 2019; 139: 2528–2536.

69. Milton Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium glucose co-transporter 2 inhibitor with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced Trial. *Eur J Heart Fail* 2019; 21: 1270–1278.

70. Anker SD, Butler J, Filippatos GS, et al. Evaluation of the effects of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. *Eur J Heart Fail* 2019; 21: 1279–1287.

71. Jensen J, Omar M, Kistorp C, et al. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF). *Trials* 2019; 20: 374.

72. Shinozaki K, Kashiwagi A, Nishio Y, et al. Abnormal pterin metabolism is a major cause of impaired endothelial-dependent relaxation through nitric oxide/O2 imbalance in insulin-resistant rat aorta. *Diabetes* 1999; 48: 2437–2445.

73. Kashiwagi A, Shibozaki K, Nishio Y, et al. Free radical production in endothelial cells as a pathogenetic factor for vascular dysfunction in the insulin-resistance state. *Diabetes Res Clin Pract* 1999; 45: 199–203.

74. Shinozaki K, Hirayama A, Nishio Y, et al. Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. *J Am Coll Cardiol* 2001; 38: 1821–1828.

75. Aoyagi T, Matsui T. The cardiomyocytes as a source of cytokines in cardiac injury. *J Cell Sci Ther* 2011. https://doi.org/10.4172/2157-7013.S5-003

76. Salim HM, Fukuda D, Yagi S, et al. Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. *Front Cardiovasc Med* 2016; 3: 1–9.

77. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. *Biochem Pharmacol* 2009; 75: 539–552.

78. Palomer X, Salvador L, Barroso E, et al. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. *Int J Cardiol* 2013; 168: 3160–3172.

79. Ansley DM, Wang B. Oxidative stress and myocardial injury in the diabetic heart*. *J Pathol* 2013; 229: 232–241.

80. Balligand JL, Ungureanu-Longrois D, Simmons WW, et al. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes: characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. *J Biol Chem* 1994; 269: 27580–27588.

81. Liu T, Zhang L, Joo D, et al. NF-kB signaling in inflammation. *Signal Transduct Target Ther* 2017; 2: 17023.

82. Tahara A, Kurosaki E, Yokono M, et al. NF-kappaB signaling in cardiac myocytes in vitro. *Int J Cardiol* 2013; 229: 232–241.

83. Garvey WT, Gaal LV, Leiter LA, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. *Eur J Pharmacol* 2013; 715: 1243–1255.

84. Smith CN, Chen S, Unger A, et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. *Circulation* 2013; 128: 2536–2543.

85. Shiell KA, Houghton M, Keogh J, et al. The efficacy of metformin in preventing the development of type 2 diabetes in people at high risk: a randomized, placebo-controlled trial. *Diabetologia* 2010; 53: 2691–2700.

86. Solomon SD, Claggett B, McMurray JJV, et al. Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. *Eur J Heart Fail* 2016; 18: 1238–1243.

87. McMurray JJV, Solomon SD, Inuzumi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2019; 381: 1995–2008.

88. Lam CS, Donal E, Kraigher-Krainer E, et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. *Eur J Heart Fail* 2011; 13: 18–28.

89. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. *N Engl J Med* 2019; 381: 1609–1620.

90. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med* 2014; 370: 1383–1392.

91. Kashiwagi A. A new door opens, but it is essential to accumulate further clinical evidence to control heart failure in diabetes with preserved ejection fraction. *J Diabetes Invest* 2019; 10: 1145–1147.

92. Soga F, Tanaka H, Tatsumi K, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. *Cardiovasc Diabetol* 2018; 17: 132–140.

93. Salim HM, Fukuda D, Yagi S, et al. Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. *Front Cardiovasc Med* 2016; 3: 1–9.

94. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. *Biochem Pharmacol* 2009; 75: 539–552.

95. Palomer X, Salvador L, Barroso E, et al. An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. *Int J Cardiol* 2013; 168: 3160–3172.

96. Ansley DM, Wang B. Oxidative stress and myocardial injury in the diabetic heart*. *J Pathol* 2013; 229: 232–241.

97. Balligand JL, Ungureanu-Longrois D, Simmons WW, et al. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes: characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. *J Biol Chem* 1994; 269: 27580–27588.

98. Liu T, Zhang L, Joo D, et al. NF-kB signaling in inflammation. *Signal Transduct Target Ther* 2017; 2: 17023.
85. Karmazyn M, Gan XT, Humphreys RA, et al. The myocardial Na\(^+\)-H\(^+\) exchange; structure, regulation, and role in heart disease. *Circ Res* 1999; 85: 777–786.

86. Packer M, Anker SD, Butler J, et al. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure; proposal of a novel mechanism of action. *JAMA Cardiol* 2017; 2: 1025–1029.

87. Hamouda NN, Sydorenko V, Qureshi MA, et al. Dapagliflozin reduces the amplitude of shortening and Ca\(^{2+}\) transient in ventricular myocytes from streptozotocin-induced diabetic rats. *Mol Cell Biochem* 2014; 400: 57–68.

88. Baartscheer A, Schumacher CA, Wust RCI, et al. Empagliflozin decreases myocardial cytoplasmic Na\(^+\) through inhibition of the cardiac Na\(^+\)/H\(^+\) exchanger in rats and rabbits. *Diabetologia* 2017; 60: 568–573.

89. Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts; inhibition of Na\(^{+}\)/H\(^{+}\) exchange, lowering of cytosolic Na\(^+\) and vasodilatation. *Diabetologia* 2018; 61: 722–726.

90. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. *Diab Vasc Dis Res* 2015; 12: 78–89.

91. Goldberg IJ, Trent CM, Schulze C. Lipid metabolism and toxicity in the heart. *Cell Metab* 2012; 15: 805–812.

92. Mizuno Y, Harada E, Nakagawa H, et al. The diabetic heart utilizes ketone bodies as an energy source. *Metabolism* 2017; 77: 65–72.

93. Sato K, Kashiwaya Y, Keon CA, et al. Insulin, ketone bodies, and mitochondrial energy transduction. *FASEB J* 1995; 9: 651–658.

94. Shimazu T, Hirschyey MD, Newman J, et al. Suppression of oxidative stress by \(\beta\)-hydroxybutyrate, an endogenous histone deacetylase inhibitor. *Science* 2013; 339: 211–214.

95. Kolwicz SC, Airhart S, Tian R, et al. Ketones step to the plate: a game changer for metabolic remodeling in heart failure? *Circulation* 2016; 133: 689–691.

96. Ferrannini E, Mark M, Mayoux E, et al. CV protection in the EMPA-REG OUTCOME Trial: a “thrifty substrate” hypothesis. *Diabetes Care* 2016; 39: 1108–1114.

97. Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. *Circulation* 2016; 133: 698–705.

98. Pachalska P, Crawford PA. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. *Cell Metab* 2017; 25: 262–284.

99. Taylor SJ, Blau JE, Rother Ki. SGLT2 inhibitors may predispose to ketoacidosis. *J Clin Endocrinol Metab* 2015; 100: 2849–2852.

100. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. *Diabetes* 2016; 65: 1190–1195.

101. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. *Diabetes Care* 2016; 39: 1115–1122.

102. Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. *Cardiovasc Diabetol* 2014; 13: 65–80.

103. Nielsen R, Möller N, Gormsen LC, et al. Cardiovascular effects of treatment with ketone body 3-hydroxybutyrate in chronic heart failure patients. *Circulation* 2019; 139: 2129–2141.